A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared With Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 06 Mar 2024
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 04 Mar 2024 According to an Amgen media release, based on data from this trial the company has received Health Canada approval for WEZLANA in all indications. WEZLANA is indicated for adult and pediatric plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
- 03 Nov 2022 According to an Amgen media release, data from the trial was submitted to FDA to support U.S. approval.
- 09 Jun 2022 Status changed from active, no longer recruiting to completed.